Cargando…
Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence
Recurrent major depressive disorder (rMDD) is a relapsing-remitting disease with high morbidity and a 5-year risk of recurrence of up to 80%. This was a prospective pilot study to examine the potential diagnostic and prognostic value of targeted plasma metabolomics in the care of patients with rMDD...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801396/ https://www.ncbi.nlm.nih.gov/pubmed/33431800 http://dx.doi.org/10.1038/s41398-020-01182-w |
_version_ | 1783635565029097472 |
---|---|
author | Mocking, Roel J. T. Naviaux, Jane C. Li, Kefeng Wang, Lin Monk, Jonathan M. Bright, A. Taylor Figueroa, Caroline A. Schene, Aart H. Ruhé, Henricus G. Assies, Johanna Naviaux, Robert K. |
author_facet | Mocking, Roel J. T. Naviaux, Jane C. Li, Kefeng Wang, Lin Monk, Jonathan M. Bright, A. Taylor Figueroa, Caroline A. Schene, Aart H. Ruhé, Henricus G. Assies, Johanna Naviaux, Robert K. |
author_sort | Mocking, Roel J. T. |
collection | PubMed |
description | Recurrent major depressive disorder (rMDD) is a relapsing-remitting disease with high morbidity and a 5-year risk of recurrence of up to 80%. This was a prospective pilot study to examine the potential diagnostic and prognostic value of targeted plasma metabolomics in the care of patients with rMDD in remission. We used an established LC-MS/MS platform to measure 399 metabolites in 68 subjects with rMDD (n = 45 females and 23 males) in antidepressant-free remission and 59 age- and sex-matched controls (n = 40 females and 19 males). Patients were then followed prospectively for 2.5 years. Metabolomics explained up to 43% of the phenotypic variance. The strongest biomarkers were gender specific. 80% of the metabolic predictors of recurrence in both males and females belonged to 6 pathways: (1) phospholipids, (2) sphingomyelins, (3) glycosphingolipids, (4) eicosanoids, (5) microbiome, and (6) purines. These changes traced to altered mitochondrial regulation of cellular redox, signaling, energy, and lipid metabolism. Metabolomics identified a chemical endophenotype that could be used to stratify rrMDD patients at greatest risk for recurrence with an accuracy over 0.90 (95%CI = 0.69–1.0). Power calculations suggest that a validation study of at least 198 females and 198 males (99 cases and 99 controls each) will be needed to confirm these results. Although a small study, these results are the first to show the potential utility of metabolomics in assisting with the important clinical challenge of prospectively identifying the patients at greatest risk of recurrence of a depressive episode and those who are at lower risk. |
format | Online Article Text |
id | pubmed-7801396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78013962021-01-21 Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence Mocking, Roel J. T. Naviaux, Jane C. Li, Kefeng Wang, Lin Monk, Jonathan M. Bright, A. Taylor Figueroa, Caroline A. Schene, Aart H. Ruhé, Henricus G. Assies, Johanna Naviaux, Robert K. Transl Psychiatry Article Recurrent major depressive disorder (rMDD) is a relapsing-remitting disease with high morbidity and a 5-year risk of recurrence of up to 80%. This was a prospective pilot study to examine the potential diagnostic and prognostic value of targeted plasma metabolomics in the care of patients with rMDD in remission. We used an established LC-MS/MS platform to measure 399 metabolites in 68 subjects with rMDD (n = 45 females and 23 males) in antidepressant-free remission and 59 age- and sex-matched controls (n = 40 females and 19 males). Patients were then followed prospectively for 2.5 years. Metabolomics explained up to 43% of the phenotypic variance. The strongest biomarkers were gender specific. 80% of the metabolic predictors of recurrence in both males and females belonged to 6 pathways: (1) phospholipids, (2) sphingomyelins, (3) glycosphingolipids, (4) eicosanoids, (5) microbiome, and (6) purines. These changes traced to altered mitochondrial regulation of cellular redox, signaling, energy, and lipid metabolism. Metabolomics identified a chemical endophenotype that could be used to stratify rrMDD patients at greatest risk for recurrence with an accuracy over 0.90 (95%CI = 0.69–1.0). Power calculations suggest that a validation study of at least 198 females and 198 males (99 cases and 99 controls each) will be needed to confirm these results. Although a small study, these results are the first to show the potential utility of metabolomics in assisting with the important clinical challenge of prospectively identifying the patients at greatest risk of recurrence of a depressive episode and those who are at lower risk. Nature Publishing Group UK 2021-01-11 /pmc/articles/PMC7801396/ /pubmed/33431800 http://dx.doi.org/10.1038/s41398-020-01182-w Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Mocking, Roel J. T. Naviaux, Jane C. Li, Kefeng Wang, Lin Monk, Jonathan M. Bright, A. Taylor Figueroa, Caroline A. Schene, Aart H. Ruhé, Henricus G. Assies, Johanna Naviaux, Robert K. Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence |
title | Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence |
title_full | Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence |
title_fullStr | Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence |
title_full_unstemmed | Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence |
title_short | Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence |
title_sort | metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801396/ https://www.ncbi.nlm.nih.gov/pubmed/33431800 http://dx.doi.org/10.1038/s41398-020-01182-w |
work_keys_str_mv | AT mockingroeljt metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT naviauxjanec metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT likefeng metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT wanglin metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT monkjonathanm metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT brightataylor metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT figueroacarolinea metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT scheneaarth metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT ruhehenricusg metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT assiesjohanna metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence AT naviauxrobertk metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence |